Jubilant Ingrevia , a leading specialty chemicals company, has reported robust financial results for the second quarter of fiscal year 2026. The company's performance showcases significant growth across key financial metrics, driven by strong performance in its Specialty Chemicals segment and improved sales volumes in Chemical Intermediates.

Financial Highlights

Segment Performance

The company's growth was primarily fueled by:

1. Specialty Chemicals: This segment demonstrated strong performance, contributing significantly to the overall revenue growth.

2. Chemical Intermediates: The company achieved its highest quarterly sales volumes in this segment over the last six quarters, indicating robust demand and improved market position.

Key Growth Drivers

• Volume Expansion: Jubilant Ingrevia experienced volume growth across multiple business areas, including:

  • CDMO (Contract Development and Manufacturing Organization)
  • Fine Chemicals
  • Acetyls business

• Pricing Pressures: Despite facing pricing pressures in some segments, the company managed to achieve growth through increased sales volumes.

Management Commentary

While specific management quotes are not provided, the results suggest that Jubilant Ingrevia's strategy of focusing on high-value segments like Specialty Chemicals and optimizing its Chemical Intermediates business is yielding positive outcomes.

The company's ability to grow its EBITDA in line with revenue, while achieving a higher growth rate in PAT, indicates improved operational efficiency and effective cost management.

Conclusion

Jubilant Ingrevia's Q2FY26 results demonstrate the company's resilience and ability to grow in a challenging market environment. The strong performance in Specialty Chemicals and record volumes in Chemical Intermediates position the company well for sustained growth. Investors and market watchers may want to keep an eye on how the company navigates pricing pressures and capitalizes on volume growth in the coming quarters.

Jubilant Ingrevia Limited (NSE: JUBLINGREA), a leading player in the specialty chemicals sector, has announced its financial results for the second quarter of fiscal year 2026, showcasing strong performance across its business segments.

Financial Highlights

The company reported an 8% year-over-year increase in EBITDA and an impressive 18% growth in Profit After Tax for Q2FY26. Here's a snapshot of the key financial metrics:

On a half-yearly basis, the company's performance was even more striking, with EBITDA growing by 18% and Profit After Tax surging by 34% compared to H1FY25.

Segment-wise Performance

Specialty Chemicals

The Specialty Chemicals segment continued to be the primary growth driver, reporting a 12% year-over-year revenue increase to Rs 485.00 crore. This segment maintained robust EBITDA margins of over 25%, driven by strong performance in Fine Chemicals and CDMO sales.

Nutrition & Health Solutions

Despite pricing pressures, the Nutrition & Health Solutions segment saw steady volume growth across core products. The segment reported revenue of Rs 181.00 crore, with an EBITDA margin of 11.60%.

Chemical Intermediates

The Chemical Intermediates segment showed significant improvement, with revenue growing 6% year-over-year to Rs 455.00 crore. This segment achieved its highest quarterly sales in terms of both value and volumes over the last six quarters.

Operational Highlights

• Successfully delivered volumes against a new Agro CDMO innovator contract in Q2.
• Added over 10 new molecules to the CDMO/Fine chemicals portfolio in the last year, expected to contribute over Rs 1,200.00 crore in peak annual revenues in coming years.
• Achieved the highest B3 volume sales in the last six quarters in the Nutrition segment.
• Expanded market share in both domestic and European markets for key Chemical Intermediate products.

Future Outlook

Looking ahead to H2FY26, Jubilant Ingrevia expects continued growth momentum, particularly in its Specialty Chemicals and Nutrition businesses. The company is on track to start serving a major CDMO order in early 2026, which is anticipated to significantly accelerate growth in the CDMO segment.

Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman, commented, "Despite challenging market conditions, we have grown revenues on the back of growth in volume-market-share and maintained profitability. Our strategic initiatives and focus on cost efficiency have enabled us to navigate through competitive pressures and maintain our market leadership in key segments."

The company's ongoing investments in capacity expansion, including the groundbreaking of a new Multi-Purpose Plant (MPP) in Gajraula, underscore its commitment to long-term growth and meeting increased demand in the CDMO sector.

With a strong pipeline of opportunities and a focus on innovation, Jubilant Ingrevia appears well-positioned to capitalize on the recovering global chemical industry landscape and drive sustainable growth in the coming quarters.

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global leader in Specialty Chemicals, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial customers. With over 40 years of experience in the chemicals industry, the company offers a diverse portfolio of more than 130 products and customized solutions. Jubilant Ingrevia operates 50 plants across 5 manufacturing facilities in India and employs over 2,300 people, including 150 scientists across its three R&D centers.